30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Edgewise Therapeutics Inc (EWTX)

Track

Over the last 90 days, Edgewise Therapeutics Inc. has seen significant insider selling, with a net value of -$2,086,354.48. This activity is primarily driven by executives, with a net count of -1 executive. The stock has experienced a 22.7% price increase over the same period, currently trading near its 52-week high.
Stock chart
Ticker: EWTX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
JOANNE DONOVAN
Officer
1 sale — total 1,572,500 USD
Proposed sale 5 May 2026
Value US$3,565,791.90 | Price 258.49 | Shares 37,371
Planned sale 5 May 2026
Value US$1,191,314.28 | Price 103.98 | Shares 58,449
Planned sale 4 May 2026
Value US$163,662.91 | Price 31.29 | Shares 5,230
Planned sale 1 Apr 2026
Value US$926,095.02 | Price 32.31 | Shares 28,662
Planned sale 31 Mar 2026
Value US$685,308.28 | Price 32.12 | Shares 21,338
Sale 27 Mar 2026
Value US$208,635.48 | Price 30.98 | Shares 6,735
Planned sale 27 Mar 2026
Value US$298,099.37 | Price 30.98 | Shares 9,623
Proposed sale 27 Mar 2026
Value US$2,265,760.20 | Price 31.65 | Shares 71,588
Planned sale 21 Jan 2026
Value US$1,957,082.88 | Price 29.44 | Shares 66,477
Planned sale 21 Jan 2026
Value US$308,030.72 | Price 29.44 | Shares 10,463
Planned sale 21 Jan 2026
Value US$223,891.20 | Price 29.44 | Shares 7,605
Planned sale 21 Jan 2026
Value US$507,427.84 | Price 29.44 | Shares 17,236
Planned sale 21 Jan 2026
Value US$403,033.60 | Price 29.44 | Shares 13,690
Proposed sale 21 Jan 2026
Value US$3,353,279.00 | Price 29.04 | Shares 115,471
Proposed sale 20 Jan 2026
Value US$5,168,722.01 | Price 28.11 | Shares 183,867
Proposed sale 15 Jan 2026
Value US$4,804,322.06 | Price 26.56 | Shares 180,872
Proposed sale 26 Dec 2025
Value US$3,039,811.57 | Price 26.06 | Shares 116,665
Proposed sale 17 Nov 2025
Value US$1,566,586.00 | Price 22.38 | Shares 70,000
Sale 12 Nov 2025
Value US$2,112,450.00 | Price 21.12 | Shares 100,000
Proposed sale 12 Nov 2025
Value US$2,112,450.00 | Price 21.12 | Shares 100,000
Buy 11 Nov 2025
Value US$199,403.06 | Price 18.64 | Shares 10,700
Sale 26 Aug 2025
Value US$1,459,760.00 | Price 14.60 | Shares 100,000
Proposed sale 26 Aug 2025
Value US$1,459,760.00 | Price 14.60 | Shares 100,000
Sale 12 Aug 2025
Value US$19,124.35 | Price 13.39 | Shares 1,428
Sale 12 Aug 2025
Value US$106,764.21 | Price 13.39 | Shares 7,972
Sale 12 Aug 2025
Value US$28,097.26 | Price 13.39 | Shares 2,098
Sale 12 Aug 2025
Value US$25,539.31 | Price 13.39 | Shares 1,907
Sale 12 Aug 2025
Value US$38,329.05 | Price 13.39 | Shares 2,862
Sale 12 Aug 2025
Value US$33,360.47 | Price 13.39 | Shares 2,491
Sale 2 May 2025
Value US$25,520.46 | Price 16.45 | Shares 1,551
Sale 2 May 2025
Value US$31,756.61 | Price 16.45 | Shares 1,930
Sale 2 May 2025
Value US$85,347.94 | Price 16.45 | Shares 5,187
Sale 2 May 2025
Value US$70,358.16 | Price 16.45 | Shares 4,276
Sale 2 May 2025
Value US$27,824.05 | Price 16.45 | Shares 1,691
Sale 2 May 2025
Value US$21,620.82 | Price 16.45 | Shares 1,314
Buy 3 Apr 2025
Value US$2,500,005.09 | Price 20.13 | Shares 124,193
Buy 3 Apr 2025
Value US$7,499,995.14 | Price 20.13 | Shares 372,578
Buy 3 Apr 2025
Value US$2,500,005.09 | Price 20.13 | Shares 124,193
Buy 3 Apr 2025
Value US$7,499,995.14 | Price 20.13 | Shares 372,578
Planned sale 7 Mar 2025
Value US$6,004.00 | Price 30.02 | Shares 200
Planned sale 7 Mar 2025
Value US$3,000.00 | Price 30.00 | Shares 100
Planned sale 6 Feb 2025
Value US$36,153.00 | Price 30.13 | Shares 1,200
Planned sale 6 Feb 2025
Value US$28,017.99 | Price 31.13 | Shares 900
Planned sale 5 Feb 2025
Value US$240,623.12 | Price 30.02 | Shares 8,015
Planned sale 5 Feb 2025
Value US$300,300.00 | Price 30.03 | Shares 10,000
Planned sale 5 Feb 2025
Value US$259,297.63 | Price 30.03 | Shares 8,636
Proposed sale 5 Feb 2025
Value US$1,192,000.00 | Price 29.80 | Shares 40,000
Proposed sale 5 Feb 2025
Value US$1,509,839.50 | Price 29.50 | Shares 51,181
Proposed sale 5 Feb 2025
Value US$2,950,000.00 | Price 29.50 | Shares 100,000
Sale 28 Jan 2025
Value US$690,657.50 | Price 27.63 | Shares 25,000
Proposed sale 28 Jan 2025
Value US$696,250.00 | Price 27.85 | Shares 25,000
Sale 30 Dec 2024
Value US$2,737,470.00 | Price 27.37 | Shares 100,000
Proposed sale 30 Dec 2024
Value US$2,874,000.00 | Price 28.74 | Shares 100,000
Sale 24 Dec 2024
Value US$52,008.84 | Price 30.08 | Shares 1,729
Planned sale 24 Dec 2024
Value US$829,906.39 | Price 29.66 | Shares 27,980
Proposed sale 24 Dec 2024
Value US$1,499,000.00 | Price 29.98 | Shares 50,000
Sale 23 Sep 2024
Value US$578,064.40 | Price 27.63 | Shares 20,922
Proposed sale 23 Sep 2024
Value US$578,064.40 | Price 27.63 | Shares 20,922
Sale 20 Sep 2024
Value US$1,221,133.08 | Price 29.03 | Shares 42,068
Sale 20 Sep 2024
Value US$24,048.53 | Price 29.51 | Shares 815
Sale 20 Sep 2024
Value US$2,096,052.66 | Price 28.25 | Shares 74,185
Sale 20 Sep 2024
Value US$1,418,510.00 | Price 28.37 | Shares 50,000
Planned sale 20 Sep 2024
Value US$202,602.95 | Price 28.29 | Shares 7,162
Sale 20 Sep 2024
Value US$1,427,385.00 | Price 28.55 | Shares 50,000
Sale 20 Sep 2024
Value US$713,511.55 | Price 28.59 | Shares 24,960
Sale 20 Sep 2024
Value US$116,174.32 | Price 28.59 | Shares 4,064
Sale 20 Sep 2024
Value US$1,316,909.06 | Price 28.59 | Shares 46,068
Proposed sale 20 Sep 2024
Value US$1,475,000.00 | Price 29.50 | Shares 50,000
Proposed sale 20 Sep 2024
Value US$202,602.95 | Price 28.29 | Shares 7,162
Proposed sale 20 Sep 2024
Value US$2,120,100.00 | Price 28.27 | Shares 75,000
Proposed sale 20 Sep 2024
Value US$3,573,979.93 | Price 28.57 | Shares 125,092
Proposed sale 20 Sep 2024
Value US$1,418,510.00 | Price 28.37 | Shares 50,000
Sale 2 May 2024
Value US$40,788.87 | Price 18.91 | Shares 2,157
Sale 2 May 2024
Value US$69,626.62 | Price 18.91 | Shares 3,682
Sale 2 May 2024
Value US$36,987.96 | Price 18.91 | Shares 1,956
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-05 2026-05-05 PrS Proposed sale
4.0
JOANNE DONOVAN

Officer

Officer
37,371
258.49
US$3,565,792 		37,371 258.49 US$3,565,792
2026-05-05 2026-05-05 PlS Planned sale
4.0
Donovan Joanne M.

CMO

Officer
58,449 -49.2%
103.98
US$1,191,314 		58,449 -49.2% 103.98 US$1,191,314
2026-05-05 2026-05-04 PlS Planned sale
4.0
Donovan Joanne M.

CMO

Officer
14,202 +46.0%
438.28
US$2,941,978 		14,202 +46.0% 438.28 US$2,941,978
2026-04-02 2026-04-01 PlS Planned sale
4.0
Donovan Joanne M.

CMO

Officer
28,662 -74.9%
32.31
US$926,095 		28,662 -74.9% 32.31 US$926,095
2026-03-31 2026-03-31 PlS Planned sale
4.0
Donovan Joanne M.

CMO

Officer
21,338 -69.0%
32.12
US$685,308 		21,338 -69.0% 32.12 US$685,308
2026-03-30 2026-03-27 S Sale
4.0
Donovan Joanne M.

CMO

Officer
6,735 -41.2%
30.98
US$208,635 		6,735 -41.2% 30.98 US$208,635
2026-03-30 2026-03-27 PlS Planned sale
4.0
Donovan Joanne M.

CMO

Officer
9,623 -37.1%
30.98
US$298,099 		9,623 -37.1% 30.98 US$298,099
2026-03-27 2026-03-27 PrS Proposed sale
4.0
JOANNE DONOVAN

Officer

Officer
71,588
31.65
US$2,265,760 		71,588 31.65 US$2,265,760
2026-01-23 2026-01-21 PlS Planned sale
Edris Badreddin
Non-Executive Director
66,477 -77.0%
29.44
US$1,957,083 		66,477 -77.0% 29.44 US$1,957,083
2026-01-23 2026-01-21 PlS Planned sale
Edris Badreddin
Non-Executive Director
10,463 -10.8%
29.44
US$308,031 		10,463 -10.8% 29.44 US$308,031
2026-01-23 2026-01-21 PlS Planned sale
Edris Badreddin
Non-Executive Director
7,605 -7.3%
29.44
US$223,891 		7,605 -7.3% 29.44 US$223,891
2026-01-23 2026-01-21 PlS Planned sale
Edris Badreddin
Non-Executive Director
17,236 -14.2%
29.44
US$507,428 		17,236 -14.2% 29.44 US$507,428
2026-01-23 2026-01-21 PlS Planned sale
Edris Badreddin
Non-Executive Director
13,690 -10.1%
29.44
US$403,034 		13,690 -10.1% 29.44 US$403,034
2026-01-21 2026-01-21 PrS Proposed sale
Badreddin Edris

Director

Non-Executive Director
115,471
29.04
US$3,353,279 		115,471 29.04 US$3,353,279
2026-01-20 2026-01-20 PrS Proposed sale
2.5
ROBERT MICHAEL CARRUTHERS

Officer

Officer
183,867
28.11
US$5,168,722 		183,867 28.11 US$5,168,722
2026-01-15 2026-01-15 PrS Proposed sale
2.5
ROBERT MICHAEL CARRUTHERS

Officer

Officer
180,872
26.56
US$4,804,322 		180,872 26.56 US$4,804,322
2025-12-29 2025-12-26 PrS Proposed sale
2.5
ROBERT MICHAEL CARRUTHERS

Officer

Officer
116,665
26.06
US$3,039,812 		116,665 26.06 US$3,039,812
2025-11-17 2025-11-17 PrS Proposed sale
2.5
ROBERT MICHAEL CARRUTHERS

Officer

Officer
70,000
22.38
US$1,566,586 		70,000 22.38 US$1,566,586
2025-11-13 2025-11-12 S Sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
100,000 -81.0%
21.12
US$2,112,450 		100,000 -81.0% 21.12 US$2,112,450
2025-11-12 2025-11-12 PrS Proposed sale
2.6
ALAN J RUSSELL

Officer; Director

Executive Director
100,000
21.12
US$2,112,450 		100,000 21.12 US$2,112,450
2025-11-13 2025-11-11 B Purchase
3.9
Fox Jonathan C
Non-Executive Director
10,700 +82.3%
18.64
US$199,403 		10,700 +82.3% 18.64 US$199,403
2025-08-28 2025-08-26 S Sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
100,000 -81.0%
14.60
US$1,459,760 		100,000 -81.0% 14.60 US$1,459,760
2025-08-26 2025-08-26 PrS Proposed sale
2.6
ALAN J RUSSELL

Officer; Director

Executive Director
100,000
14.60
US$1,459,760 		100,000 14.60 US$1,459,760
2025-08-14 2025-08-12 S Sale
2.5
Carruthers R Michael

Chief Financial Officer

Officer
1,428 -1.6%
13.39
US$19,124 		1,428 -1.6% 13.39 US$19,124
2025-08-14 2025-08-12 S Sale
2.5
KOCH KEVIN

President and CEO

Executive Director
7,972 -20.7%
13.39
US$106,764 		7,972 -20.7% 13.39 US$106,764
2025-08-14 2025-08-12 S Sale
2.3
MOORE JOHN R

General Counsel

Officer
2,098 -17.0%
13.39
US$28,097 		2,098 -17.0% 13.39 US$28,097
2025-08-14 2025-08-12 S Sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
1,907 -7.5%
13.39
US$25,539 		1,907 -7.5% 13.39 US$25,539
2025-08-14 2025-08-12 S Sale
4.0
Donovan Joanne M.

CMO

Officer
2,862 -10.1%
13.39
US$38,329 		2,862 -10.1% 13.39 US$38,329
2025-08-14 2025-08-12 S Sale
2.7
Derakhshan Behrad

Chief Business Officer

Officer
2,491 -9.5%
13.39
US$33,360 		2,491 -9.5% 13.39 US$33,360
2025-05-07 2025-05-02 S Sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
1,551 -7.7%
16.45
US$25,520 		1,551 -7.7% 16.45 US$25,520
2025-05-07 2025-05-02 S Sale
2.3
MOORE JOHN R

General Counsel

Officer
1,930 -22.8%
16.45
US$31,757 		1,930 -22.8% 16.45 US$31,757
2025-05-07 2025-05-02 S Sale
4.0
Donovan Joanne M.

CMO

Officer
5,187 -19.4%
16.45
US$85,348 		5,187 -19.4% 16.45 US$85,348
2025-05-07 2025-05-02 S Sale
2.5
KOCH KEVIN

President and CEO

Executive Director
4,276 -17.2%
16.45
US$70,358 		4,276 -17.2% 16.45 US$70,358
2025-05-07 2025-05-02 S Sale
2.7
Derakhshan Behrad

Chief Business Officer

Officer
1,691 -7.7%
16.45
US$27,824 		1,691 -7.7% 16.45 US$27,824
2025-05-07 2025-05-02 S Sale
2.5
Carruthers R Michael

Chief Financial Officer

Officer
1,314 -1.6%
16.45
US$21,621 		1,314 -1.6% 16.45 US$21,621
2025-04-04 2025-04-03 B Purchase
3.0
Thompson Peter A.
Non-Executive Director Large shareholder
124,193 +38.9%
20.13
US$2,500,005 		124,193 +38.9% 20.13 US$2,500,005
2025-04-04 2025-04-03 B Purchase
3.0
Thompson Peter A.
Non-Executive Director Large shareholder
372,578 +2.6%
20.13
US$7,499,995 		372,578 +2.6% 20.13 US$7,499,995
2025-04-04 2025-04-03 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
124,193 +38.9%
20.13
US$2,500,005 		124,193 +38.9% 20.13 US$2,500,005
2025-04-04 2025-04-03 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
372,578 +2.6%
20.13
US$7,499,995 		372,578 +2.6% 20.13 US$7,499,995
2025-03-11 2025-03-07 PlS Planned sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
200 -1.3%
30.02
US$6,004 		200 -1.3% 30.02 US$6,004
2025-03-11 2025-03-07 PlS Planned sale
2.5
KOCH KEVIN

President and CEO

Executive Director
100 -0.7%
30.00
US$3,000 		100 -0.7% 30.00 US$3,000
2025-02-07 2025-02-06 PlS Planned sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
1,200 -7.5%
30.13
US$36,153 		1,200 -7.5% 30.13 US$36,153
2025-02-07 2025-02-06 PlS Planned sale
2.5
KOCH KEVIN

President and CEO

Executive Director
900 -5.9%
31.13
US$28,018 		900 -5.9% 31.13 US$28,018
2025-02-07 2025-02-05 PlS Planned sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
8,015 -35.0%
30.02
US$240,623 		8,015 -35.0% 30.02 US$240,623
2025-02-07 2025-02-05 PlS Planned sale
2.7
Derakhshan Behrad

Chief Business Officer

Officer
10,000 -37.3%
30.03
US$300,300 		10,000 -37.3% 30.03 US$300,300
2025-02-07 2025-02-05 PlS Planned sale
2.5
KOCH KEVIN

President and CEO

Executive Director
8,636 -37.4%
30.03
US$259,298 		8,636 -37.4% 30.03 US$259,298
2025-02-05 2025-02-05 PrS Proposed sale
2.7
Behrad Derakhshan

Officer

Officer
40,000
29.80
US$1,192,000 		40,000 29.80 US$1,192,000
2025-02-05 2025-02-05 PrS Proposed sale
2.5
KEVIN KOCH

Director; Officer

Executive Director
51,181
29.50
US$1,509,840 		51,181 29.50 US$1,509,840
2025-02-05 2025-02-05 PrS Proposed sale
2.6
ALAN J RUSSELL

Director; Officer

Executive Director
100,000
29.50
US$2,950,000 		100,000 29.50 US$2,950,000
2025-01-30 2025-01-28 S Sale
4.0
Donovan Joanne M.

CMO

Officer
25,000 -60.4%
27.63
US$690,658 		25,000 -60.4% 27.63 US$690,658
2025-01-28 2025-01-28 PrS Proposed sale
4.0
JOANNE DONOVAN

Officer

Officer
25,000
27.85
US$696,250 		25,000 27.85 US$696,250
2024-12-31 2024-12-30 S Sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
100,000 -87.1%
27.37
US$2,737,470 		100,000 -87.1% 27.37 US$2,737,470
2024-12-30 2024-12-30 PrS Proposed sale
2.6
ALAN J RUSSELL

Director; Officer

Executive Director
100,000
28.74
US$2,874,000 		100,000 28.74 US$2,874,000
2024-12-27 2024-12-24 S Sale
3.2
Semigran Marc

Chief Development Officer

Officer
1,729 -20.5%
30.08
US$52,009 		1,729 -20.5% 30.08 US$52,009
2024-12-27 2024-12-24 PlS Planned sale
3.2
Semigran Marc

Chief Development Officer

Officer
27,980 -76.8%
29.66
US$829,906 		27,980 -76.8% 29.66 US$829,906
2024-12-26 2024-12-24 PrS Proposed sale
3.2
MARC J SEMIGRAN

Officer

Officer
50,000
29.98
US$1,499,000 		50,000 29.98 US$1,499,000
2024-09-24 2024-09-23 S Sale
2.3
MOORE JOHN R

General Counsel

Officer
20,922 -86.5%
27.63
US$578,064 		20,922 -86.5% 27.63 US$578,064
2024-09-23 2024-09-23 PrS Proposed sale
2.3
JOHN R MOORE

Officer

Officer
20,922
27.63
US$578,064 		20,922 27.63 US$578,064
2024-09-24 2024-09-20 S Sale
2.7
Derakhshan Behrad

Chief Business Officer

Officer
42,068 -73.6%
29.03
US$1,221,133 		42,068 -73.6% 29.03 US$1,221,133
2024-09-24 2024-09-20 S Sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
815 -6.0%
29.51
US$24,049 		815 -6.0% 29.51 US$24,049
2024-09-24 2024-09-20 S Sale
2.6
Russell Alan J

Chief Scientific Officer

Executive Director
74,185 -84.6%
28.25
US$2,096,053 		74,185 -84.6% 28.25 US$2,096,053
2024-09-24 2024-09-20 S Sale
2.3
MOORE JOHN R

General Counsel

Officer
50,000 -93.9%
28.37
US$1,418,510 		50,000 -93.9% 28.37 US$1,418,510
2024-09-24 2024-09-20 PlS Planned sale
4.0
Donovan Joanne M.

CMO

Officer
7,162 -33.0%
28.29
US$202,603 		7,162 -33.0% 28.29 US$202,603
2024-09-24 2024-09-20 S Sale
2.5
Carruthers R Michael

Chief Financial Officer

Officer
50,000 -87.9%
28.55
US$1,427,385 		50,000 -87.9% 28.55 US$1,427,385
2024-09-24 2024-09-20 S Sale
2.5
Carruthers R Michael

Chief Financial Officer

Officer
24,960 -78.3%
28.59
US$713,512 		24,960 -78.3% 28.59 US$713,512
2024-09-24 2024-09-20 S Sale
2.5
Carruthers R Michael

Chief Financial Officer

Officer
4,064 -11.3%
28.59
US$116,174 		4,064 -11.3% 28.59 US$116,174
2024-09-24 2024-09-20 S Sale
2.5
Carruthers R Michael

Chief Financial Officer

Officer
46,068 -56.2%
28.59
US$1,316,909 		46,068 -56.2% 28.59 US$1,316,909
2024-09-20 2024-09-20 PrS Proposed sale
2.7
Behrad Derakhshan

Officer

Officer
50,000
29.50
US$1,475,000 		50,000 29.50 US$1,475,000
2024-09-20 2024-09-20 PrS Proposed sale
4.0
JOANNE DONOVAN

Officer

Officer
7,162
28.29
US$202,603 		7,162 28.29 US$202,603
2024-09-20 2024-09-20 PrS Proposed sale
2.6
ALAN J RUSSELL

Officer; Director

Executive Director
75,000
28.27
US$2,120,100 		75,000 28.27 US$2,120,100
2024-09-20 2024-09-20 PrS Proposed sale
2.5
ROBERT MICHAEL CARRUTHERS

Officer

Officer
125,092
28.57
US$3,573,980 		125,092 28.57 US$3,573,980
2024-09-20 2024-09-20 PrS Proposed sale
2.3
JOHN R MOORE

Officer

Officer
50,000
28.37
US$1,418,510 		50,000 28.37 US$1,418,510
2024-05-03 2024-05-02 S Sale
2.5
Carruthers R Michael

Chief Financial Officer

Officer
2,157 -5.8%
18.91
US$40,789 		2,157 -5.8% 18.91 US$40,789
2024-05-03 2024-05-02 S Sale
4.0
Donovan Joanne M.

CMO

Officer
3,682 -15.6%
18.91
US$69,627 		3,682 -15.6% 18.91 US$69,627
2024-05-03 2024-05-02 S Sale
2.3
MOORE JOHN R

General Counsel

Officer
1,956 -37.6%
18.91
US$36,988 		1,956 -37.6% 18.91 US$36,988
Explore more

More insider trading research around Edgewise Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America